This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ViroPharma Provides Update From Ongoing Phase 2 Studies Of Maribavir For Treatment Of Cytomegalovirus (CMV) Infections

In the study of resistant/refractory CMV, among 31 subjects receiving maribavir, 26 (84 percent) achieved BQL during therapy, 4 subjects failed to achieve BQL while on therapy, and 1 subject had withdrawn for non-virologic reasons prior to achieving BQL.  Eleven of the 26 subjects who achieved BQL subsequently experienced virologic breakthrough while on treatment. 

As a reminder, these studies are ongoing, so different subjects have been followed for different periods of time.  Also all subjects will continue to be followed after the end of treatment to monitor for the return of detectable plasma CMV DNA when off antiviral therapy (which is not uncommon following the use of currently available anti-CMV therapies). 

To date, in both ongoing studies maribavir appears to demonstrate a favorable safety and tolerability profile. An independent data monitoring committee is monitoring the studies, and to date it has convened once to review data from the asymptomatic study with no findings of concern.  Adverse events seen in these studies appear generally consistent with those expected in transplant recipient populations and what has been observed in more than 1,000 patients who have received maribavir in previous clinical studies.

"The results we've seen to date are very positive and encouraging," stated Vincent Milano, ViroPharma's president and chief executive officer.  "We appear to have very good response – about 90 percent - in treating asymptomatic CMV viremia, which is what one would expect for a potent anti-CMV treatment.  Not surprisingly, the resistant/refractory patients are more complicated, and we are seeing nearly 85 percent of patients attaining undetectable viral levels and a sustained antiviral response through the end of treatment in roughly half of the enrolled subjects, which is impressive given the lack of treatment options and high unmet need in these patients.  There remain a number of elements of the studies which we will not be able to fully analyze until after study completion (including effects of maribavir dose, pre-treatment viral load, emergence of viral resistance and various patient factors). These data are consistent with what we had hoped to see and had seen in previous clinical experiences with maribavir as a treatment for CMV.  We are now fully committed to this development program and intend to focus on accelerating the completion of both studies.  As a result, moving forward, we intend to limit the number of future interim data disclosures."

About Maribavir

Maribavir, a member of a new class of drugs called benzimidazole ribosides, is a potent and selective, orally bioavailable antiviral drug with a unique mechanism of action against cytomegalovirus and a favorable clinical safety profile. Unlike currently available anti-CMV agents that inhibit CMV DNA polymerase, maribavir inhibits viral DNA assembly and inhibits egress of viral capsids from the nucleus of infected cells. Maribavir is active in vitro against strains of CMV that are resistant to commonly used anti-CMV drugs. Maribavir does not affect the maturation of viral DNA or affect the viral DNA polymerase. The previous focus of clinical development of maribavir as an anti-CMV agent was on the prevention of CMV disease in transplant patients.  Results from Phase 3 studies indicated that maribavir at a dose of 100mg BID failed to meet its efficacy endpoints.  However, maribavir has demonstrated a favorable safety and tolerability profile; across all clinical studies to date, the most notable adverse event associated with maribavir was taste disturbance.  While Phase 3 studies of CMV prophylaxis at the 100mg BID dose did not show sufficient activity to prevent CMV disease, limited data from cases in which open-label maribavir was used as CMV treatment suggest that higher doses may provide clinical activity and clinical studies are ongoing. The U.S. Food and Drug Administration (FDA) and the European Commission have granted orphan drug designation to maribavir for treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients, and the prevention and treatment of cytomegalovirus disease in patients with impaired cell mediated immunity, respectively.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.91 -0.76%
FB $118.09 0.02%
GOOG $699.31 0.52%
TSLA $213.56 -4.00%
YHOO $37.01 2.80%


Chart of I:DJI
DOW 17,686.02 +34.76 0.20%
S&P 500 2,053.44 +2.32 0.11%
NASDAQ 4,730.30 +4.6610 0.10%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs